Fulgent Genetics, Inc. (FLGT) Form 8-K — Jul 30, 2026
Fulgent Genetics reported second quarter 2026 revenue of $85.4 million, representing a 4.3% increase year-over-year and 20.1% growth sequentially. The company posted a GAAP net loss of $29.5 million, or $(1.05) per share, and a non-GAAP net loss of $16.2 million, or $(0.58) per share. The company revised its full-year 2026 revenue guidance to a range of $330.0 million to $340.0 million, citing processing delays related to the transition of its revenue cycle management and billing system. Fulgent also announced it executed on its stock repurchase program, purchasing approximately 1.5 million shares for $23.8 million in cash during the quarter.
Key figures
- Revenue
- 85400000
- Guidance
- Revenue to be in the range of $330.0-$340.0 million
- Cash Position
- 551500000
- Gross Proceeds
- 23800000
- Shares Offered
- 1500000
- Shares Outstanding
- 28005000
- F ID007 Phase2 ORR
- 61.9%
- Tax Refund Expected
- 106100000
- Revenue Sequential Growth
- 20.1%
- Adjusted Purchase Price Acquisitions
- 56400000
Price after filing
Close on the filing date to close N calendar days later (from $19.63). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.